PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

New England Journal of Medicine

Volumn 372, Issue 4, 2015, Pages 311-319

  Ansell, Stephen M ^a   Lesokhin, Alexander M ^b,c   Borrello, Ivan ^d   Halwani, Ahmad ^e   Scott, Emma C ^f   Gutierrez, Martin ^g   Schuster, Stephen J ⁱ   Millenson, Michael M ^j   Cattry, Deepika ^b   Freeman, Gordon J ^k,m   Rodig, Scott J ^l   Chapuy, Bjoern ^k,m   Ligon, Azra H ^m   Zhu, Lili ^h   Grosso, Joseph F ^h   Kim, Su Young ^h   Timmerman, John M ⁿ   Shipp, Margaret A ^k,m   Armand, Philippe ^k,m  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN; JANUS KINASE; NIVOLUMAB; PHOSPHOPROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; STAT3 PROTEIN; TRIACYLGLYCEROL LIPASE; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; STAT PROTEIN;

ADULT; ALLERGIC REACTION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENE DOSAGE; GENE LOCUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; LEUKOPENIA; LYMPH NODE PAIN; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; PANCREATITIS; PDL1 GENE; PDL2 GENE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; RECEPTOR BLOCKING; REED STERNBERG CELL; SHORT SURVEY; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR BIOPSY; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; JANUS KINASES; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; RECURRENCE; REED-STERNBERG CELLS; STAT TRANSCRIPTION FACTORS; STEM CELL TRANSPLANTATION;

EID: 84925221855     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1411087     Document Type: Article

References (27)

1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
2. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer - preclinical background: CTLA-and PD-1 blockade. Semin Oncol 2010;37:430-9.
3. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
5. Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19:462-8.
6. Taube JM, Klein AP, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-74.
7. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 2011;17:4232-44.
8. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013;31: 4199-206.
9. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-51.
10. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77.
11. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009;114:2149-58.
12. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107: 3639-46.
13. Keytruda (pembrolizumab). Whitehouse Station, NJ: Merck (package insert) (http://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf).
14. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116:3268-77.
15. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galec-tin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007; 104:13134-9.
16. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471:377-81.
17. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012;18:1611-8.
18. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
20. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Bethesda, MD: Department of Health and Human Services, 2009. (NIH publication no. 09-7473.)
21. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400-8.
22. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013;54:2531-3.
23. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12: 1065-72.
24. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9.
25. Steidl C, Telenius A, Shah SP, et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 2010;116:418-27.
26. Carbone A, Gloghini A, Zanette I, Canal B, Rizzo A, Volpe R. Co-expression of Epstein-Barr virus latent membrane protein and vimentin in "aggressive" histological subtypes of Hodgkin's disease. Virchows Arch A Pathol Anat Histopathol 1993;422:39-45.
27. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 2008; 105:15016-21.